Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

by Raza Azra, Galili Naomi, Mulford Deborah, Smith Scott E, Brown Gail L, Steensma David P, Lyons Roger M, Boccia Ralph, Sekeres Mikkael A, Garcia-Manero Guillermo, Mesa Ruben A
Published 2012-04-01